-
公开(公告)号：US07576115B2
公开(公告)日：2009-08-18
申请号：US11837659
申请日：2007-08-13
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/415 , C07D231/10
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当A是氮原子时，B不是NH），R1是C2 -14芳基，L1是键，CR10R11，氧原子，硫原子或NR12，X是OR13，SR13或NR14NR15，R2是氢原子，甲酰基，C1-10烷基等， L2是键或类似物，L3是键，CR17R18，氧原子，硫原子或NR19，L4是键，CR20R21，氧原子，硫原子或NR22，Y是氧原子，硫原子 原子或NR 23，并且R 3是C 12-14芳基，互变异构体，前药或化合物或其溶剂合物的药学上可接受的盐。
-
公开(公告)号：US20060094694A1
公开(公告)日：2006-05-04
申请号：US11294609
申请日：2005-12-06
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： A61K31/675 , C07D261/12 , C07D231/08 , A61K31/42 , A61K31/4152
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。
-
公开(公告)号：US07351841B2
公开(公告)日：2008-04-01
申请号：US11294609
申请日：2005-12-06
申请人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
发明人： Shingo Owada , Shunsuke Iwamoto , Kazufumi Yanagihara , Katsuaki Miyaji , Takanori Nakamura , Norihisa Ishiwata , Yutaka Hirokawa
IPC分类号： C07D333/12 , C07D333/16 , C07D333/18 , C07D333/20 , C07D333/32 , C07D333/34 , A61K31/381
CPC分类号： C07D417/12 , C07D231/18 , C07D295/192 , C07D333/32 , C07D333/38 , C07D403/12 , C07D409/12
摘要： A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（1）表示的化合物：其中A是氮原子或CR 4，B是氧原子，硫原子或NR 9（条件是当 A是氮原子，B不是NH），R 1是C 2-14芳基，L 1是一个键， 氧原子，硫原子或NR 12，X是OR 13， 或者NR 14是NR 15，R 2是氢原子，甲酰基，C 1 -C 6烷基， 1-10个烷基等，L 2是一个键或类似物，L 3是一个键，CR 17 R 18是氧原子，硫原子或NR 19，L 4是键，CR 20 R 21，氧原子，硫原子或NR 22，Y是氧原子，硫原子或NR 23，和 R 3是C 2-14芳基，该化合物的互变异构体，前药或药学上可接受的盐或其溶剂化物。
-
公开(公告)号：US08026368B2
公开(公告)日：2011-09-27
申请号：US12092834
申请日：2006-11-07
IPC分类号： C07D401/00 , A61K31/44
CPC分类号： C07D409/12 , C07D409/14
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20090253751A1
公开(公告)日：2009-10-08
申请号：US12092834
申请日：2006-11-07
IPC分类号： A61K31/4439 , C07D409/12 , C07D409/14 , A61K31/415
CPC分类号： C07D409/12 , C07D409/14
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
16.发明申请公开(公告)号：US20090198060A1
公开(公告)日：2009-08-06
申请号：US12303436
申请日：2007-06-07
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
IPC分类号： C07D403/12 , C07D401/12
CPC分类号： C07D231/22 , C07D401/12 , C07D403/12
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
17.发明授权Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators 有权含氮杂环化合物和血小板生成素受体激活剂公开(公告)号：US08093251B2
公开(公告)日：2012-01-10
申请号：US12303436
申请日：2007-06-07
申请人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
发明人： Katsuaki Miyaji , Shunsuke Iwamoto , Yukihiro Shigeta , Yutaka Hirokawa , Shingo Oowada , Takanori Nakamura , Norihisa Ishiwata
IPC分类号： C07D401/12 , C07D403/12 , A61K31/454 , A61K31/496 , A61P7/00
CPC分类号： C07D231/22 , C07D401/12 , C07D403/12
摘要： Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided.A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 提供了有效预防，治疗或改善血小板生成素受体激活有效的疾病的化合物。 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3，L1，L2，L3，X和Y在说明书中定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20090131676A1
公开(公告)日：2009-05-21
申请号：US11995070
申请日：2006-07-19
IPC分类号： C07D409/14 , C07D409/12
CPC分类号： C07D409/14 , C07D409/12
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US07960425B2
公开(公告)日：2011-06-14
申请号：US11995070
申请日：2006-07-19
IPC分类号： A61K31/4155 , C07D231/18
CPC分类号： C07D409/14 , C07D409/12
摘要： A compound represented by the formula (I) (wherein R1, R2, R3 and R4 are as defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.
摘要翻译： 由式（I）表示的化合物或其溶剂化物，其中R1，R2，R3和R4如说明书中所定义），互变异构体，前药或药学上可接受的盐。
-
公开(公告)号：US20100310537A1
公开(公告)日：2010-12-09
申请号：US12746507
申请日：2008-12-05
CPC分类号： C12N5/0647 , A61K35/12 , C12N2501/125 , C12N2501/145 , C12N2501/999
摘要： An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells.A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.07 秒)
